Why You Should Consider Adding Omnicell Stock to Your Portfolio Today
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Should l Buy CAH?
Source: NASDAQ.COM
Omnicell's Growth Potential: Omnicell's SaaS and Expert Services are expected to drive growth, supported by a strong market performance and a solid solvency position, despite facing intense competition in the medication management sector.
International Expansion Plans: The company aims to expand its operations internationally, targeting under-penetrated markets in Canada, Europe, the Middle East, and Asia-Pacific, where healthcare providers are increasingly recognizing the benefits of automation.
Financial Stability: Omnicell reported a favorable liquidity position with cash exceeding total debt, indicating a strong capital structure, while the earnings consensus for 2025 shows positive growth expectations.
Competitive Landscape: Despite gaining market share, Omnicell faces significant competition from major players in the industry, which could lead to pricing pressures and impact profit margins.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAH
Wall Street analysts forecast CAH stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 215.060
Low
209.00
Averages
225.18
High
244.00
Current: 215.060
Low
209.00
Averages
225.18
High
244.00
About CAH
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardinal Health Announces Quarterly Dividend Approval
- Quarterly Dividend Approval: Cardinal Health's Board of Directors has approved a quarterly dividend of $0.5107 per share, reflecting the company's strong capital surplus management, which is expected to enhance investor confidence and attract more shareholders.
- Payment Schedule: The dividend will be payable on April 15, 2026, to shareholders of record as of April 1, 2026, ensuring timely returns for investors and further solidifying the relationship between the company and its shareholders.
- Company Background: Cardinal Health is a global distributor of pharmaceuticals and medical products, focusing on customer needs and driving innovative solutions aimed at improving people's quality of life, highlighting its significant role in the healthcare industry.
- Market Impact: The announcement of this dividend not only reflects the company's healthy financial status but may also positively influence its stock price, attracting more investor interest in its future growth potential.
See More
Becton, Dickinson and Company Stock in Focus
- Intensifying Market Competition: Becton, Dickinson faces fierce competition in the medical device distribution sector, particularly as Boston Scientific's dominance in the pulse field ablation market is challenged, indicating that changing market dynamics could impact the company's performance.
- Investment Potential Assessment: While Becton, Dickinson is viewed as a potential investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, implying that investors should be cautious in their selections.
- Diverse Medical Supply Portfolio: Becton, Dickinson sells a significant variety of medical supplies, diagnostic tools, and lab equipment, widely used by healthcare professionals and researchers, highlighting its importance and demand in the healthcare industry.
- Market Dynamics Observation: Jim Cramer expresses a bullish view on Becton, Dickinson, suggesting that its performance in the medical device sector is worth monitoring, reflecting investor optimism about the company's future prospects.
See More
Cardinal Health CFO Discusses Impact of Healthcare Policies
- Impact of Subsidy Changes: As the Trump administration's healthcare policies evolve, particularly with the expiration of Affordable Care Act subsidies at the end of 2025, Cardinal Health has not yet observed a decline in demand, indicating the company's resilience in the face of potential patient cost increases.
- Trends in Healthcare Demand: With the aging American population, healthcare demand continues to rise, and Cardinal Health aligns with government goals to enhance access, affordability, and innovation, aiming to optimize the overall efficiency of the healthcare ecosystem.
- Tariff Pressure Management: In response to tariff pressures, Cardinal Health has adopted a transparent pricing strategy within its medical products business, where, despite efforts to enhance operational efficiency, the company has raised prices on key products to offset rising costs, reflecting market realities.
- Market Adaptability: Despite facing policy and market challenges, Cardinal Health is committed to maintaining accessibility and innovation in healthcare services through collaboration with the government, ensuring competitiveness in a rapidly changing healthcare environment.
See More
Healthcare Stocks Shine with McKesson Up 16.6%
- Healthcare Sector Performance: In Thursday's trading, healthcare stocks emerged as the best-performing sector, rising by 0.2%, with McKesson Corp (MCK) leading the charge with a 16.6% gain, indicating strong market demand that could attract more investor interest in the sector.
- Cardinal Health's Gains: Cardinal Health, Inc. (CAH) also performed well, with a 9.0% increase, suggesting a solid position in the healthcare supply chain that may further enhance its market share and investor confidence.
- ETF Trends: Despite the overall positive performance in healthcare, the Health Care Select Sector SPDR ETF (XLV) fell by 0.5%, indicating a preference for individual stocks over ETFs, which may lead to a shift in capital towards more promising equities.
- Utilities Sector Stability: The utilities sector showed relative stability, with CMS Energy Corp (CMS) up 2.4% and PPL Corp (PPL) up 1.4%, reflecting investor preference for stable returns, which may attract more capital into this sector in the future.
See More
Significant Stock Movements in Midday Trading
- McKesson Earnings Beat: McKesson's fiscal third-quarter earnings per share exceeded Wall Street's highest estimates, and the adjusted full-year EPS guidance was raised above analyst consensus, leading to a 16% stock price increase, indicating strong performance in the medical supply sector.
- Bob's Discount Furniture IPO: Bob's Discount Furniture debuted on the New York Stock Exchange with shares priced at $17, recently rising 10%, marking a successful entry into the public market and laying the groundwork for future growth.
- Fluence Energy Earnings Miss: Fluence Energy reported first-quarter revenue of $475.2 million, falling short of the $481.2 million consensus, with a per-share loss of 34 cents missing the 21-cent loss estimate, resulting in a 31% stock price drop, reflecting market concerns over its profitability.
- Cardinal Health Guidance Raised: Cardinal Health reported quarterly adjusted earnings of $2.63 per share, exceeding the $2.36 consensus, with revenue of $65.63 billion surpassing the $64.14 billion estimate, leading to an 8% stock price increase, showcasing strong growth potential in the healthcare services sector.
See More
Cardinal Health Shares Surge; Another Guidance Increase Could Propel Them Further.
- Fiscal-Year Outlook Increase: Cardinal Health has raised its fiscal-year outlook for the second time in less than a month.
- Positive Financial Performance: The company’s recent adjustments indicate strong financial performance and confidence in future growth.
See More
Cardinal Health Announces Quarterly Dividend Approval
- Quarterly Dividend Approval: Cardinal Health's Board of Directors has approved a quarterly dividend of $0.5107 per share, reflecting the company's strong capital surplus management, which is expected to enhance investor confidence and attract more shareholders.
- Payment Schedule: The dividend will be payable on April 15, 2026, to shareholders of record as of April 1, 2026, ensuring timely returns for investors and further solidifying the relationship between the company and its shareholders.
- Company Background: Cardinal Health is a global distributor of pharmaceuticals and medical products, focusing on customer needs and driving innovative solutions aimed at improving people's quality of life, highlighting its significant role in the healthcare industry.
- Market Impact: The announcement of this dividend not only reflects the company's healthy financial status but may also positively influence its stock price, attracting more investor interest in its future growth potential.
See More
Becton, Dickinson and Company Stock in Focus
- Intensifying Market Competition: Becton, Dickinson faces fierce competition in the medical device distribution sector, particularly as Boston Scientific's dominance in the pulse field ablation market is challenged, indicating that changing market dynamics could impact the company's performance.
- Investment Potential Assessment: While Becton, Dickinson is viewed as a potential investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, implying that investors should be cautious in their selections.
- Diverse Medical Supply Portfolio: Becton, Dickinson sells a significant variety of medical supplies, diagnostic tools, and lab equipment, widely used by healthcare professionals and researchers, highlighting its importance and demand in the healthcare industry.
- Market Dynamics Observation: Jim Cramer expresses a bullish view on Becton, Dickinson, suggesting that its performance in the medical device sector is worth monitoring, reflecting investor optimism about the company's future prospects.
See More
Cardinal Health CFO Discusses Impact of Healthcare Policies
- Impact of Subsidy Changes: As the Trump administration's healthcare policies evolve, particularly with the expiration of Affordable Care Act subsidies at the end of 2025, Cardinal Health has not yet observed a decline in demand, indicating the company's resilience in the face of potential patient cost increases.
- Trends in Healthcare Demand: With the aging American population, healthcare demand continues to rise, and Cardinal Health aligns with government goals to enhance access, affordability, and innovation, aiming to optimize the overall efficiency of the healthcare ecosystem.
- Tariff Pressure Management: In response to tariff pressures, Cardinal Health has adopted a transparent pricing strategy within its medical products business, where, despite efforts to enhance operational efficiency, the company has raised prices on key products to offset rising costs, reflecting market realities.
- Market Adaptability: Despite facing policy and market challenges, Cardinal Health is committed to maintaining accessibility and innovation in healthcare services through collaboration with the government, ensuring competitiveness in a rapidly changing healthcare environment.
See More
Healthcare Stocks Shine with McKesson Up 16.6%
- Healthcare Sector Performance: In Thursday's trading, healthcare stocks emerged as the best-performing sector, rising by 0.2%, with McKesson Corp (MCK) leading the charge with a 16.6% gain, indicating strong market demand that could attract more investor interest in the sector.
- Cardinal Health's Gains: Cardinal Health, Inc. (CAH) also performed well, with a 9.0% increase, suggesting a solid position in the healthcare supply chain that may further enhance its market share and investor confidence.
- ETF Trends: Despite the overall positive performance in healthcare, the Health Care Select Sector SPDR ETF (XLV) fell by 0.5%, indicating a preference for individual stocks over ETFs, which may lead to a shift in capital towards more promising equities.
- Utilities Sector Stability: The utilities sector showed relative stability, with CMS Energy Corp (CMS) up 2.4% and PPL Corp (PPL) up 1.4%, reflecting investor preference for stable returns, which may attract more capital into this sector in the future.
See More
Significant Stock Movements in Midday Trading
- McKesson Earnings Beat: McKesson's fiscal third-quarter earnings per share exceeded Wall Street's highest estimates, and the adjusted full-year EPS guidance was raised above analyst consensus, leading to a 16% stock price increase, indicating strong performance in the medical supply sector.
- Bob's Discount Furniture IPO: Bob's Discount Furniture debuted on the New York Stock Exchange with shares priced at $17, recently rising 10%, marking a successful entry into the public market and laying the groundwork for future growth.
- Fluence Energy Earnings Miss: Fluence Energy reported first-quarter revenue of $475.2 million, falling short of the $481.2 million consensus, with a per-share loss of 34 cents missing the 21-cent loss estimate, resulting in a 31% stock price drop, reflecting market concerns over its profitability.
- Cardinal Health Guidance Raised: Cardinal Health reported quarterly adjusted earnings of $2.63 per share, exceeding the $2.36 consensus, with revenue of $65.63 billion surpassing the $64.14 billion estimate, leading to an 8% stock price increase, showcasing strong growth potential in the healthcare services sector.
See More
Cardinal Health Shares Surge; Another Guidance Increase Could Propel Them Further.
- Fiscal-Year Outlook Increase: Cardinal Health has raised its fiscal-year outlook for the second time in less than a month.
- Positive Financial Performance: The company’s recent adjustments indicate strong financial performance and confidence in future growth.
See More
